Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DW-MSCs
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
DW-MSCs are allogeneic **mesenchymal stem cells** (MSCs) manufactured from human embryonic stem cells (line SNUhES35) according to Good Manufacturing Practice (GMP) standards. These cells are expanded, characterized (CD29, CD44, CD73, CD105 positive; negative for hematopoietic and pluripotency markers), and tested for sterility and quality prior to use. DW-MSCs can differentiate into chondroblasts, osteoblasts, and adipocytes. Their main mechanism is **immunomodulation** via paracrine signaling and interaction with host immune cells, with a potential for regenerative effects. The primary clinical indication studied to date is the treatment of COVID-19, specifically in patients with low clinical risk. DW-MSCs are delivered as a single intravenous infusion and are being evaluated for safety and early signs of efficacy in clinical trials[1][2][7]. The product is manufactured by the National Institute of Health, National Center for Stem Cell and Regenerative Medicine in Korea[1].
- Brand names
- DW-MSCs
Beyond the preview
Go deeper on DW-MSCs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DW-MSCs.